Innovation

Turning Research Into Impact

Our research has led to a number of technological advances with commercial potential, enabling us to form a spin-out company. Our spin-out is generating tools and techniques that will assist their customers' businesses.

Spin-out company

GenieBiome is established by a team of internationally renowned professors of medicine and clinician-scientists from The Chinese University of Hong Kong. They are among the global top echelon of researchers in the field of gut microbiome with strong academic standing and novel technologies.

​

90% of us are dominated by microbes in our bodies. GenieBiome pioneers the use of novel microbes as diagnostic markers and potential remedies for different diseases. With an exploding body of global research indicating that the gut microbiome plays a central role in health and disease, GenieBiome has rapidly positioned itself to be a leading force in the development of new diagnostics and therapeutics based on the gut microbiome. It combines cutting-edge and disruptive technologies into a pipeline that enables the prediction of early cancers and debilitating chronic diseases. 

​

Utilizing our unique in-house dataset and those from publicly available sources, we have identified novel microbes as reliable, non-invasive biomarkers and developed proprietary machine-learning algorithms that can accurately predict disease risk.  

The G-NiiB Immunity product, a microbiome precision formula that improves immunity against Coronavirus (COVID)-19 and other respiratory infections tailored to Asians. 

Products